These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 28971574)

  • 1. Aberrant lipid metabolism in cancer cells - the role of oncolipid-activated signaling.
    Ray U; Roy SS
    FEBS J; 2018 Feb; 285(3):432-443. PubMed ID: 28971574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells.
    Mukherjee A; Wu J; Barbour S; Fang X
    J Biol Chem; 2012 Jul; 287(30):24990-5000. PubMed ID: 22665482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid desaturation - the next step in targeting lipogenesis in cancer?
    Peck B; Schulze A
    FEBS J; 2016 Aug; 283(15):2767-78. PubMed ID: 26881388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis.
    Gotoh M; Fujiwara Y; Yue J; Liu J; Lee S; Fells J; Uchiyama A; Murakami-Murofushi K; Kennel S; Wall J; Patil R; Gupte R; Balazs L; Miller DD; Tigyi GJ
    Biochem Soc Trans; 2012 Feb; 40(1):31-6. PubMed ID: 22260662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis.
    Tigyi GJ; Yue J; Norman DD; Szabo E; Balogh A; Balazs L; Zhao G; Lee SC
    Adv Biol Regul; 2019 Jan; 71():183-193. PubMed ID: 30243984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice.
    Li HY; Oh YS; Choi JW; Jung JY; Jun HS
    Kidney Int; 2017 Jun; 91(6):1362-1373. PubMed ID: 28111010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of adipocyte differentiation and lipid accumulation by stearidonic acid (SDA) in 3T3-L1 cells.
    Li Y; Rong Y; Bao L; Nie B; Ren G; Zheng C; Amin R; Arnold RD; Jeganathan RB; Huggins KW
    Lipids Health Dis; 2017 Sep; 16(1):181. PubMed ID: 28946872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid metabolism reprogramming and its potential targets in cancer.
    Cheng C; Geng F; Cheng X; Guo D
    Cancer Commun (Lond); 2018 May; 38(1):27. PubMed ID: 29784041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of LPA receptor signaling in breast cancer.
    Wang J; Sun Y; Qu J; Yan Y; Yang Y; Cai H
    Expert Rev Mol Diagn; 2016 Oct; 16(10):1103-1111. PubMed ID: 27644846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth.
    Du X; Wang QR; Chan E; Merchant M; Liu J; French D; Ashkenazi A; Qing J
    Cancer Res; 2012 Nov; 72(22):5843-55. PubMed ID: 23019225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysophosphatidic Acid Signaling in Obesity and Insulin Resistance.
    D'Souza K; Paramel GV; Kienesberger PC
    Nutrients; 2018 Mar; 10(4):. PubMed ID: 29570618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autotaxin and LPA receptor signaling in cancer.
    Houben AJ; Moolenaar WH
    Cancer Metastasis Rev; 2011 Dec; 30(3-4):557-65. PubMed ID: 22002750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysophosphatidic acid (LPA) receptor-mediated signaling and cellular responses to anticancer drugs and radiation of cancer cells.
    Ikeda H; Takai M; Tsujiuchi T
    Adv Biol Regul; 2024 May; 92():101029. PubMed ID: 38377635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLP-1 Elicits an Intrinsic Gut-Liver Metabolic Signal to Ameliorate Diet-Induced VLDL Overproduction and Insulin Resistance.
    Khound R; Taher J; Baker C; Adeli K; Su Q
    Arterioscler Thromb Vasc Biol; 2017 Dec; 37(12):2252-2259. PubMed ID: 29074588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autotaxin⁻Lysophosphatidic Acid Signaling in Alzheimer's Disease.
    Ramesh S; Govindarajulu M; Suppiramaniam V; Moore T; Dhanasekaran M
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29933579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accumulation of lipids and oxidatively damaged DNA in hepatocytes exposed to particles.
    Vesterdal LK; Danielsen PH; Folkmann JK; Jespersen LF; Aguilar-Pelaez K; Roursgaard M; Loft S; Møller P
    Toxicol Appl Pharmacol; 2014 Jan; 274(2):350-60. PubMed ID: 24121055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of lysophosphatidic acid pathway modulators as therapies for fibrosis.
    Budd DC; Qian Y
    Future Med Chem; 2013 Oct; 5(16):1935-52. PubMed ID: 24175745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling.
    Seo MH; Lee J; Hong SW; Rhee EJ; Park SE; Park CY; Oh KW; Park SW; Lee WY
    PLoS One; 2016; 11(12):e0166913. PubMed ID: 27907035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiforme.
    Tabuchi S
    Lipids Health Dis; 2015 Jun; 14():56. PubMed ID: 26084470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allyl isothiocyanate suppresses the proteolytic activation of sterol regulatory element-binding proteins and de novo fatty acid and cholesterol synthesis.
    Miyata S; Inoue J; Shimizu M; Sato R
    Biosci Biotechnol Biochem; 2016 May; 80(5):1006-11. PubMed ID: 26822063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.